Smart wound dressing for treating chronic diabetic ulcers

用于治疗慢性糖尿病溃疡的智能伤口敷料

基本信息

  • 批准号:
    9124291
  • 负责人:
  • 金额:
    $ 26.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-03-01 至 2017-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): ( Non-healing wounds caused by diabetes mellitus account for one of the most common complications of this disease leading to increased healthcare cost, decreased quality of life, infections, amputations, and death. The wide prevalence of this disease and its projected increase in the near future has further necessitated therapeutics aimed at enhancing the healing of diabetic wounds. Vascularization and oxygenation are critical parameters in wound healing process. In healing tissue, sufficient oxygenation is critical because of the increased energy demand for reparative processes such as cell proliferation, bacterial defense and collagen synthesis. In normal acute wounds, neoangiogenesis and vascularization result in tissue oxygenation. However, in chronic diabetic wounds, angiogenesis is impaired; thus, severe hypoxia results in insufficient energy for healing, excessive inflammation, and bacterial infection. Although exogenous vascular endothelial growth factor (VEGF) has shown to improve neoangiogenesis, the lack of oxygen significantly reduces the healing rate. Our hypothesis is that the proper oxygenation of wound combined with the delivery of angiogenic factors such as VEGF will enhance the healing process and enable the immune cells to eradicate colonized pathogens. Our approach is to make a smart wound dressing by continuously monitoring epidermal oxygen concentration in the wound area as a measure of angiogenesis and locally releasing VEGF and oxygen which are essential for the healing process on demand. In addition to improve the effectiveness of the therapy and accuracy of measurements, we proposed to bypass the debridement by using microneedles which have already proven to be more effective. We propose to develop this advanced and clinically relevant technology using the following steps: 1) fabricating VEGF eluting microneedles on a flexible substrate; 2) engineering microneedle-based oxygen sensors as well as flexible oxygen generation and delivery modules and their integration; and 3) evaluate the in vivo functionality of the engineered platform in diabetic wound models. The proposed design not only could sense the wound environment, but also can control release VEGF and modulate the tissue oxygenation.
描述(由申请人提供):(糖尿病引起的不愈合伤口是该疾病最常见的并发症之一,导致医疗费用增加、生活质量下降、感染、截肢和死亡。这种疾病的广泛流行及其在不久的将来的预计增加进一步需要旨在促进糖尿病伤口愈合的治疗。血管化和氧合是伤口愈合过程中的关键参数。在愈合组织中,充分的氧合是至关重要的,因为修复过程(如细胞增殖、细菌防御和胶原蛋白合成)的能量需求增加。在正常的急性伤口中,新血管生成和血管形成导致组织氧合。然而,在慢性糖尿病伤口中,血管生成受损;因此,严重缺氧导致用于愈合的能量不足、过度炎症和细菌感染。虽然外源性血管内皮生长因子(VEGF)已显示出改善新血管生成,缺氧显着降低愈合率。我们的假设是,伤口的适当氧合结合血管生成因子如VEGF的递送将增强愈合过程,并使免疫细胞能够根除定植的病原体。我们的方法是通过连续监测伤口区域的表皮氧浓度来制造智能伤口敷料,作为血管生成的量度,并根据需要局部释放对愈合过程至关重要的VEGF和氧气。除了提高治疗的有效性和测量的准确性之外,我们还提出通过使用已经被证明更有效的微针来绕过清创术。我们建议使用以下步骤开发这种先进的临床相关技术:1)在柔性基底上制造VEGF洗脱微针; 2)工程化基于微针的氧传感器以及柔性氧产生和递送模块及其集成; 3)评估工程化平台在糖尿病伤口模型中的体内功能。该设计不仅可以感知伤口环境,而且可以控制VEGF的释放和调节组织氧合。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ali Khademhosseini其他文献

Ali Khademhosseini的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ali Khademhosseini', 18)}}的其他基金

Drug eluting injectable biomaterials for next generation chemoembolization
用于下一代化疗栓塞的药物洗脱可注射生物材料
  • 批准号:
    10397659
  • 财政年份:
    2021
  • 资助金额:
    $ 26.63万
  • 项目类别:
Healing enterocutaneous fistulas using bioengineered biomaterials
使用生物工程生物材料治愈肠皮瘘
  • 批准号:
    10384769
  • 财政年份:
    2021
  • 资助金额:
    $ 26.63万
  • 项目类别:
Drug eluting injectable biomaterials for next generation chemoembolization
用于下一代化疗栓塞的药物洗脱可注射生物材料
  • 批准号:
    10620134
  • 财政年份:
    2021
  • 资助金额:
    $ 26.63万
  • 项目类别:
Drug eluting injectable biomaterials for next generation chemoembolization
用于下一代化疗栓塞的药物洗脱可注射生物材料
  • 批准号:
    10230909
  • 财政年份:
    2021
  • 资助金额:
    $ 26.63万
  • 项目类别:
Healing enterocutaneous fistulas using bioengineered biomaterials
使用生物工程生物材料治愈肠皮瘘
  • 批准号:
    10532787
  • 财政年份:
    2021
  • 资助金额:
    $ 26.63万
  • 项目类别:
Treatment of arterial aneurysms using an injectable biomaterial
使用可注射生物材料治疗动脉瘤
  • 批准号:
    10171610
  • 财政年份:
    2018
  • 资助金额:
    $ 26.63万
  • 项目类别:
Treatment of arterial aneurysms using an injectable biomaterial
使用可注射生物材料治疗动脉瘤
  • 批准号:
    9883832
  • 财政年份:
    2018
  • 资助金额:
    $ 26.63万
  • 项目类别:
Engineering personalized micro-tumor ecosystems
设计个性化微肿瘤生态系统
  • 批准号:
    10261573
  • 财政年份:
    2017
  • 资助金额:
    $ 26.63万
  • 项目类别:
Engineering personalized micro-tumor ecosystems
设计个性化微肿瘤生态系统
  • 批准号:
    9981696
  • 财政年份:
    2017
  • 资助金额:
    $ 26.63万
  • 项目类别:
Targeted chemotherapy delivery and capture
靶向化疗递送和捕获
  • 批准号:
    9913518
  • 财政年份:
    2017
  • 资助金额:
    $ 26.63万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 26.63万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了